Oscar Health
OSCR
$21.14
-7.97%
Oscar Health, Inc. is a healthcare technology company that offers Individual & Family health insurance plans primarily through federal and state-run Affordable Care Act (ACA) exchanges, while also providing a full-stack technology platform to power the healthcare industry. The company positions itself as a technology-driven disruptor within the traditional managed care sector, aiming to improve member experience and administrative efficiency through its proprietary platform. The current investor narrative is sharply divided between the company's significant revenue growth and its persistent quarterly losses, with recent news highlighting a potential value opportunity as the stock's price decline contrasts with its member growth and a clearer path to profitability, especially amid a favorable regulatory backdrop for Medicare Advantage payments that benefits the broader sector.…
OSCR
Oscar Health
$21.14
Related headlines
Investment Opinion: Should I buy OSCR Today?
Rating: Hold. The core thesis is that OSCR presents a high-risk, high-potential-reward situation where explosive momentum and deep value are counterbalanced by fundamental profitability flaws, making it suitable only for speculative capital within a diversified portfolio. Supporting evidence for this cautious stance includes the severely discounted PS ratio of 0.32, which suggests most bad news is priced in. Revenue growth remains robust at 17.25% YoY, and analyst forward revenue estimates average $28.23B. Critically, the company generates substantial positive free cash flow ($1.06B TTM), providing a financial runway. However, these positives are offset by the deep net loss of -$352.6M in Q4, gross margin compression to 6.6%, and a high beta of 2.34 that signals extreme volatility. The thesis would upgrade to a Buy if OSCR can demonstrate two consecutive quarters of gross margin stabilization above 15% and narrowing net losses, confirming a turnaround. It would downgrade to a Sell if quarterly revenue growth decelerates below 10% or if the current ratio deteriorates further below 0.9, signaling heightened liquidity risk. Relative to its own history and the challenges it faces, the stock is fairly valued at current levels—the low sales multiple accurately reflects the high execution risk, while the forward PE of 15.89 embeds optimistic earnings expectations.
Sign up to view all
OSCR 12-Month Price Forecast
OSCR is a binary turnaround story where the current price balances deep-value potential against profound operational risk. The substantial cash flow and low sales multiple create a margin of safety, but the path to consistent profitability remains unproven and highly volatile. The recent analyst upgrades and sector tailwinds provide a supportive backdrop, but the stock's extreme volatility makes it a trading vehicle as much as an investment. The stance would upgrade to bullish on evidence of sustained margin improvement (e.g., two quarters >15% gross margin) and downgrade to bearish on a breakdown of key technical support near $20 coupled with deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Oscar Health's 12-month outlook, with a consensus price target around $27.48 and implied upside of +30.0% versus the current price.
Average Target
$27.48
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$17 - $27
Analyst target range
Analyst coverage for Oscar Health is limited, with only 3 analysts providing estimates, indicating it is a smaller-cap stock with less institutional following which can lead to higher volatility. The consensus sentiment appears mixed, as institutional ratings show recent upgrades from Sell to Neutral (UBS) and Underweight to Equal Weight (Barclays), alongside a separate upgrade to Overweight (Piper Sandler), suggesting a cautiously improving but not yet bullish view. The average revenue estimate for the forward period is $28.23 billion, with a wide range from $26.41 billion to $29.14 billion, but a consensus price target is not provided in the data, preventing a calculation of implied upside. The wide range between the low and high revenue estimates, a spread of over $2.7 billion, signals high uncertainty among analysts regarding the company's near-term growth trajectory. The high estimate likely assumes successful membership growth, stable margins, and perhaps market share gains, while the low estimate may price in competitive pressures, membership attrition, or adverse medical cost trends. The recent pattern of rating upgrades from key firms, however, suggests a growing belief that the worst may be over and that the risk/reward profile is improving, even if full conviction remains elusive.
Bulls vs Bears: OSCR Investment Factors
The investment debate for OSCR centers on a stark tension between its extreme valuation discount and its persistent, volatile losses. The bull case, currently supported by stronger evidence from surging price momentum, robust cash flow, and sector tailwinds, argues that the market's deep pessimism (PS ratio of 0.32) has overshot, creating a deep-value opportunity if management can stabilize margins. The bear case rightly highlights the severe and unpredictable gross margin compression (from 25.8% to 6.6% in one year) and consistent net losses as fundamental flaws that justify the low multiple. The single most important factor that will resolve this debate is the company's ability to demonstrate quarter-over-quarter consistency in its medical cost ratio and gross margin, moving from a story of volatile growth to one of predictable, scaled profitability.
Bullish
- Extreme Valuation Discount: OSCR trades at a trailing PS ratio of 0.32, an extreme discount from its historical highs above 8.0. This deep value multiple prices in significant pessimism, offering substantial upside if the company demonstrates a credible path to profitability.
- Strong Revenue Growth Trajectory: The company delivered 17.25% YoY revenue growth in Q4 2025, with analysts forecasting forward revenue of $28.23 billion. This robust top-line expansion, driven by ACA marketplace membership, underpins the growth narrative despite quarterly volatility.
- Powerful Positive Cash Flow: OSCR generated $1.058 billion in trailing twelve-month free cash flow, yielding a strong FCF margin. This substantial internal cash generation provides a crucial lifeline to fund operations and growth without excessive external financing, mitigating liquidity concerns.
- Sector Tailwinds and Improving Sentiment: Recent favorable Medicare Advantage payment updates from CMS have boosted the entire managed care sector. This, coupled with analyst upgrades from Sell/Underweight to Neutral/Equal Weight, signals a cautiously improving fundamental and sentiment backdrop.
Bearish
- Persistent and Volatile Losses: OSCR posted a Q4 2025 net loss of -$352.6 million, with a trailing net margin of -3.79%. Profitability is highly inconsistent, swinging from a $275.3 million profit in Q1 to a deep loss in Q4, highlighting severe underwriting and operational challenges.
- Severe Gross Margin Compression: Quarterly gross margin collapsed from 25.8% in Q1 2025 to just 6.6% in Q4 2025. This extreme volatility and compression reflect the difficult economics of the insurance business and medical cost uncertainty, directly threatening the path to sustainable profits.
- High Volatility and Beta Risk: With a beta of 2.34, OSCR is approximately 134% more volatile than the market. This extreme volatility, evidenced by a 52-week range of $10.69 to $25.58, makes the stock unsuitable for risk-averse investors and amplifies downside during market corrections.
- Weak Short-Term Liquidity: The company's current ratio of 0.95 indicates potential strain in meeting short-term obligations. This liquidity concern, coupled with a negative ROE of -45.33%, raises questions about financial stability despite positive operating cash flow.
OSCR Technical Analysis
The prevailing price trend for Oscar Health is a volatile but strong recovery, with the stock posting a 61.087% gain over the past year. As of the latest close at $22.23, the stock is trading at approximately 87% of its 52-week range ($10.69 to $25.58), indicating it is near recent highs and demonstrating significant momentum off its lows. This positioning suggests the market is pricing in improved fundamentals, though it also raises the risk of a pullback if growth expectations are not met. Recent short-term momentum is exceptionally strong and accelerating, with the stock up 23.9822% over the past month and 62.9765% over the past three months. This powerful surge significantly outpaces the broader market, as evidenced by a relative strength of 52.6965 over three months versus the SPY. The divergence from a weaker six-month performance of +23.7062% indicates a major inflection point in sentiment and price action, likely driven by fundamental catalysts or sector-wide tailwinds. Key technical levels are the 52-week low of $10.69, which now serves as major support, and the 52-week high of $25.58, which is the immediate resistance target. A decisive breakout above $25.58 would signal a continuation of the bullish trend and potentially open the door to new highs, while a breakdown below the recent consolidation area near $20 would suggest profit-taking. The stock's beta of 2.341 indicates it is approximately 134% more volatile than the market, which is critical for risk management as it implies amplified moves both up and down.
Beta
2.34
2.34x market volatility
Max Drawdown
-51.7%
Largest decline past year
52-Week Range
$11-$26
Price range past year
Annual Return
+48.2%
Cumulative gain past year
| Period | OSCR Return | S&P 500 |
|---|---|---|
| 1m | +14.3% | +5.4% |
| 3m | +40.5% | +10.9% |
| 6m | +23.1% | +11.0% |
| 1y | +48.2% | +28.1% |
| ytd | +41.2% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OSCR Fundamental Analysis
Oscar Health's revenue trajectory is one of robust growth, with Q4 2025 revenue reaching $2.805 billion, representing a 17.25% year-over-year increase. However, examining the quarterly trend reveals volatility; revenue declined sequentially from $3.046 billion in Q1 2025 to the Q4 level, indicating potential seasonality or membership churn within the ACA marketplace. The growth is primarily driven by its core insurance membership, as segment data is not available, but the overall double-digit annual growth supports the company's expansion narrative despite quarterly fluctuations. The company remains unprofitable, with a Q4 2025 net income of -$352.611 million and a trailing net margin of -3.79%. Gross margin for the quarter was a thin 6.6%, a significant compression from the 25.8% reported in Q1 2025, highlighting the challenging economics and medical cost volatility in the insurance business. The path to profitability is uneven, as losses widened considerably in Q4 compared to a profit of $275.271 million in Q1, underscoring the operational and underwriting challenges the company faces in achieving consistent earnings. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.44, indicating a manageable capital structure. Liquidity is a concern with a current ratio of 0.95, suggesting potential strain in meeting short-term obligations. Positively, the company generated substantial trailing twelve-month free cash flow of $1.058 billion, yielding a strong FCF margin and providing internal funding for growth. The return on equity is deeply negative at -45.33%, reflecting the significant losses relative to shareholder capital, but the positive operating cash flow offers a crucial lifeline.
Quarterly Revenue
$2.8B
2025-12
Revenue YoY Growth
+0.17%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OSCR Overvalued?
Given Oscar Health's negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 0.322, which is exceptionally low and reflects the market's deep discount due to persistent losses. A forward PE ratio of 15.89 is available, indicating the market anticipates a significant turnaround to profitability in the coming year, creating a stark contrast between current losses and future earnings expectations. Comparing to industry averages is challenging due to missing sector-specific data in the provided valuation set. However, a PS ratio of 0.32 is generally far below typical multiples for growth-oriented healthcare technology or insurance companies, even those with losses. This substantial discount likely prices in significant execution risk, regulatory uncertainty, and the history of volatile margins, but it may also present a deep value opportunity if the company's growth and path to profitability materialize as projected. Historically, Oscar Health's current PS ratio of 0.322 is near the very bottom of its own range, having traded as high as 1.45 in Q4 2025 and above 8.0 in 2021. This extreme compression from its historical highs suggests the market has completely reset expectations, moving from a high-growth, high-multiple story to a deep-value, show-me narrative. Trading at these historical lows implies either a profound value opportunity or a fundamental deterioration that the multiple accurately reflects.
PE
-8.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -28x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-3.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, centered on profitability and margin stability. The company's net margin is deeply negative at -3.79%, with quarterly gross margin exhibiting extreme volatility, collapsing from 25.8% to 6.6% within 2025. This indicates poor control over medical costs (the largest expense for an insurer) and unreliable underwriting. While free cash flow is strong at $1.06 billion, the weak current ratio of 0.95 suggests potential liquidity strain in covering short-term claims and expenses, and the business remains dependent on continued high revenue growth to justify any investment while losses persist. Market & Competitive Risks are elevated due to valuation, volatility, and sector dynamics. Although the PS ratio of 0.32 is deeply discounted, the forward PE of 15.89 implies the market is pricing in a significant earnings turnaround; failure to deliver could trigger multiple compression. The stock's beta of 2.34 means it will experience amplified swings relative to the market, increasing portfolio risk. As a disruptor in the ACA exchange market, OSCR faces intense competition from entrenched, profitable giants like UnitedHealth and CVS Health, which have greater scale and pricing power, especially in a sector recently buoyed by Medicare Advantage tailwinds that may not directly benefit OSCR's core individual market. Worst-Case Scenario involves a combination of accelerated membership attrition, another severe medical cost spike that crushes gross margins, and a broader market downturn. This could break investor confidence in the path to profitability, leading to a re-test of the 52-week low of $10.69. Given the current price of $22.23, this scenario implies a realistic downside of approximately -52%. A sustained period of losses could also pressure the balance sheet, eroding the positive cash flow cushion and potentially necessitating dilutive capital raises, further depressing the stock price.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: Inability to achieve consistent GAAP profits, as evidenced by a Q4 2025 net loss of -$352.6M and gross margin collapsing to 6.6%. 2) Volatility Risk: A beta of 2.34 means the stock will experience wild swings, potentially eroding capital quickly. 3) Operational Risk: Dependence on the competitive and regulated ACA individual market, with revenue concentration in that segment. 4) Liquidity Risk: A current ratio of 0.95 indicates potential difficulty covering short-term obligations despite positive operating cash flow.
Our 12-month outlook presents three scenarios. The Base Case (50% probability) sees the stock trading between $20 and $25, as volatile performance continues without a decisive breakout. The Bull Case (30% probability), driven by margin stabilization and profitability, targets $28 to $35. The Bear Case (20% probability), triggered by worsening losses, sees a drop to the $10.69 - $16 range. The base case is most likely, predicated on the assumption that OSCR will show modest improvement but not enough to trigger a full valuation re-rating, keeping the stock range-bound amid high volatility.
OSCR appears deeply undervalued on a price-to-sales basis, trading at a PS ratio of 0.32, which is near the bottom of its historical range. However, this discount directly reflects its fundamental challenges: negative net margins and volatile profitability. The forward PE of 15.89 suggests the market is already pricing in a significant earnings recovery. Therefore, the stock is fairly valued relative to its current risk profile—the market is paying a bargain price for a business with unproven economics. The valuation implies the market expects either a successful turnaround or continued stagnation.
OSCR is a speculative buy only for investors with a high risk tolerance and a long-term horizon. The stock offers significant potential upside due to its deeply discounted valuation (PS ratio of 0.32) and strong revenue growth (17.25% YoY). However, this is counterbalanced by severe risks: persistent quarterly losses, extreme gross margin volatility, and market volatility 134% above average (beta 2.34). It could be a good buy for a small, speculative portion of a portfolio if you believe management can execute a turnaround, but it is not a suitable core holding.
OSCR is primarily suited for long-term, speculative investment with a minimum horizon of 3-5 years to allow its turnaround narrative to potentially play out. Its high beta (2.34) and lack of dividends make it a poor income or short-term trading stock, as daily volatility can be punishing. However, the powerful momentum (up 63% in 3 months) also attracts short-term traders. For most investors, a long-term hold approach is appropriate to capture the full value of a successful business model transition, but they must be prepared for a very bumpy ride and the possibility of permanent capital loss.